Expanding orders in the patent and pharmaceutical sectors and securing preferred-vendor and long-term contracts

「特許事務所において、コスト抑制を背景とした業務の内製化や発注方針の見直しを検討する動きがあり、受注が低調に推移した結果、売上高は前年同期比10.6％減の702百万円となりました。医薬分野では前年同期に好調であった外資製薬の特定の大口顧客およびCRO（医薬品開発業務受託機関）からの受注が総じて弱含みで推移したことに加え、前年同期に複数の内資製薬から受注したスポット案件の反動減も影響し、売上高は前年同期比20.4％減の495百万円となりました。」

「In the patents segment, the start of business with new large customers and increased orders from patent law firms resulted in revenue of ¥2,945 million, up 1.1% year on year, despite lower orders from some large corporate intellectual property customers. In the pharmaceuticals segment, although orders increased from certain large customers of foreign pharmaceutical companies and the company won several large projects from domestic pharmaceutical companies, revenue was essentially flat year on year at ¥2,677 million, partly because orders from CROs declined from the second quarter onward.」

「In the patents segment, although orders from some large corporate intellectual property customers declined, the start of business with new large customers and increased orders from its major customers, patent law firms, resulted in revenue of ¥1,491 million, up 0.3% year on year. In the pharmaceuticals segment, increased orders from certain large customers of foreign pharmaceutical companies and growth in orders from CROs contributed to revenue of ¥1,284 million, up 5.0% year on year.」

「In the patents segment, although orders from some large corporate intellectual property customers declined, orders from patent law firms remained strong, resulting in revenue of ¥2,911 million, up 0.3% year on year. In the pharmaceuticals segment, while building ongoing relationships with customers and expanding its customer base to capture demand, orders from foreign pharmaceutical companies grew in the fourth quarter, alongside increased orders from domestic pharmaceutical companies and the capture of strong demand from several CRO customers, resulting in revenue of ¥2,694 million, up 3.4% year on year.」

「In the patents segment, although orders from some large corporate intellectual property customers declined, orders from patent law firms remained strong, resulting in revenue of ¥1,486 million, up 2.6% year on year. In the pharmaceuticals segment, while building ongoing relationships with customers and expanding its customer base to capture demand, the company saw increased orders from domestic pharmaceutical companies and CROs versus the previous year. However, sluggish orders from foreign pharmaceutical companies resulted in revenue of ¥1,222 million, down 0.8% year on year.」

「In the patents segment, orders from its major customers, patent law firms and corporate intellectual property departments, remained strong, resulting in revenue of ¥2,902 million, up 7.1% year on year. In the pharmaceuticals segment, the company worked to strengthen relationships with customers to expand orders for new-drug development-related documents, but orders from domestic pharmaceutical companies remained virtually flat year on year. In addition, lower orders from foreign pharmaceutical companies, foreign CROs, and medical-device companies resulted in revenue of ¥2,605 million, down 6.8% year on year.」

「In the patents segment, orders from its major customers, patent law firms and corporate intellectual property departments, remained strong, as in the previous period, resulting in revenue of ¥1,447 million, up 8.8% year on year. In the pharmaceuticals segment, business with domestic pharmaceutical companies was on a recovery trend due to increased orders from several customers, but lower orders from foreign pharmaceutical companies and foreign CROs resulted in revenue of ¥1,232 million, down 8.7% year on year.」

「In the patents segment, orders from its major customers, patent law firms and corporate intellectual property departments, remained strong, as in the previous period, resulting in revenue of ¥719 million, up 13.8% year on year. In the pharmaceuticals segment, although orders from foreign pharmaceutical companies remained firm, sluggish business with domestic pharmaceutical companies and lower orders from CROs resulted in revenue of ¥618 million, down 5.4% year on year.」

「In the patents segment, strong orders from its major customers, patent law firms and corporate intellectual property departments, resulted in revenue of ¥2,708 million, up 16.9% year on year. In the pharmaceuticals segment, translation demand remained sluggish due to customers' testing schedules, while lower orders from CROs and a decline following projects related to COVID-19 won in the previous period resulted in revenue of ¥2,796 million, down 3.7% year on year. In the industrial and localization segment, business remained solid, primarily with manufacturing customers, and the acquisition of large projects from information and communications companies resulted in revenue of ¥2,376 million, up 17.2% year on year. In the financial and legal segment, orders for IR-related documents increased following the restructuring of the Tokyo Stock Exchange's market segments, but revenue declined 0.7% year on year to ¥575 million due to a decline following the large project from an insurance company acquired in the previous period.」

「In the patents segment, strong orders from its major customers, patent law firms and corporate intellectual property departments, resulted in revenue of ¥2,023 million, up 18.3% year on year. In the pharmaceuticals segment, translation demand remained sluggish due to customers' testing schedules, while lower orders from CROs and a decline following projects related to COVID-19 won in the previous period resulted in revenue of ¥2,041 million, down 6.1% year on year.」

「In the patents segment, strong orders from its major customers, patent law firms and corporate intellectual property departments, together with sales contributed by information and communications companies, resulted in revenue of ¥1,329 million, up 18.2% year on year. In the pharmaceuticals segment, translation demand temporarily declined due to customers' testing schedules, while lower orders from CROs and a decline following projects related to COVID-19 won in the previous period resulted in revenue of ¥1,350 million, down 6.7% year on year.」

「In the patents segment, orders from its major customers, patent law firms, remained strong, as in the previous period, and the acquisition of large projects from corporate intellectual property departments resulted in revenue of ¥631 million, up 13.5% year on year. In the pharmaceuticals segment, translation demand temporarily declined due to customers' testing schedules, and lower orders from CROs also contributed to revenue of ¥654 million, down 8.5% year on year.」

「In the patents segment, strong sales to its major customers, patent law firms, resulted in revenue of ¥2,316 million, up 10.2% year on year. In the pharmaceuticals segment, strong orders from foreign pharmaceutical companies and solid business with domestic pharmaceutical companies resulted in revenue of ¥2,904 million, up 1.0% year on year.」

「In the patents segment, strong sales to its major customers, patent law firms, resulted in revenue of ¥1,710 million, up 9.4% year on year. In the pharmaceuticals segment, continued strong orders from foreign pharmaceutical companies and solid business with domestic pharmaceutical companies resulted in revenue of ¥2,175 million, up 4.7% year on year.」

「In the patents segment, strong sales to its major customers, patent law firms, resulted in revenue of ¥1,124 million, up 10.2% year on year. In the pharmaceuticals segment, continued strong orders from foreign pharmaceutical companies and solid business with domestic pharmaceutical companies resulted in revenue of ¥1,448 million, up 7.9% year on year.」

「In the patents segment, sales to its major customers, patent law firms, remained strong, resulting in revenue of ¥556 million, up 12.4% year on year. In the pharmaceuticals segment, where revenue also increased in the previous period, orders from foreign pharmaceutical companies remained strong and business with domestic pharmaceutical companies also grew, resulting in revenue of ¥715 million, up 8.5% year on year.」

「In the patents segment, sluggish orders from patent law firms resulted in revenue of ¥2,100 million, down 7.0% year on year. In the pharmaceuticals segment, strong orders from foreign pharmaceutical companies and solid business with domestic pharmaceutical companies resulted in revenue of ¥2,875 million, up 4.5% year on year.」

「In the patents segment, sluggish orders from patent law firms resulted in revenue of ¥1,562 million, down 8.1% year on year. In the pharmaceuticals segment, solid orders from foreign pharmaceutical companies and expanding business with domestic pharmaceutical companies resulted in revenue of ¥2,076 million, up 2.4% year on year.」

「Although some recovery was seen in domestic economic activity, the translation business remained sluggish except in the pharmaceuticals segment due to stagnation in customers' international business activities. In the patents segment, sluggish orders from corporate intellectual property departments and patent law firms resulted in revenue of ¥1,019 million, down 12.3% year on year. In the pharmaceuticals segment, stable orders from foreign pharmaceutical companies and solid business with domestic pharmaceutical companies resulted in revenue of ¥1,341 million, up 2.0% year on year.」

「In the patents segment, orders from corporate intellectual property departments and patent law firms remained sluggish due to restrictions on corporate activity, resulting in revenue of ¥494 million, down 15.0% year on year. In the pharmaceuticals segment, strong orders from foreign pharmaceutical companies and expanding business with domestic pharmaceutical companies resulted in revenue of ¥659 million, up 10.7% year on year.」

「In the patents segment, orders from patent law firms remained strong against a backdrop of increased international filings, and business with corporate intellectual property departments also remained solid, resulting in revenue of ¥1,701 million, up 7.9% year on year. In the pharmaceuticals segment, although orders remained firm, revenue declined 5.5% year on year to ¥2,027 million due to the impact of fewer inspections conducted at major customers, pharmaceutical companies, during the period. The company is pursuing initiatives including the joint development of AI translation to expand its services for pharmaceutical companies.」

「In the patents segment, demand for translation remained strong against a backdrop of increased international filings, and orders from patent law firms remained strong. Combined with increased orders from corporate intellectual property departments, this resulted in revenue of ¥1,163 million, up 12.5% year on year. In the pharmaceuticals segment, although orders from major customers, including pharmaceutical companies, remained firm, revenue declined 4.4% year on year to ¥1,314 million as the decline following large projects recorded in the same period of the previous year could not be fully offset.」

「In the patents segment, demand for translation remained strong against a backdrop of increased international filings, and orders from patent law firms remained strong. Combined with increased orders from corporate intellectual property departments, this resulted in revenue of ¥581 million, up 16.9% year on year. In the pharmaceuticals segment, although the company won large projects from several pharmaceutical companies, revenue declined 18.2% year on year to ¥595 million due in part to a decline following the spot project involving new-drug application materials recorded in the same period of the previous year.」

「In the patents segment, in addition to strong orders from its major customers, patent law firms, business with corporate intellectual property departments remained solid, resulting in revenue of ¥2,139 million, up 13.7% year on year. In the pharmaceuticals segment, in addition to stable orders from domestic and foreign pharmaceutical companies, business with CROs remained solid, resulting in revenue of ¥2,897 million, up 5.5% year on year.」

「In the patents segment, in addition to strong orders from patent law firms, business with corporate intellectual property departments remained solid, resulting in revenue of ¥1,576 million, up 11.6% year on year. In the pharmaceuticals segment, expanding business with foreign pharmaceutical companies resulted in revenue of ¥2,146 million, up 7.0% year on year.」

「In the patents segment, orders from patent law firms remained strong, resulting in revenue of ¥1,033 million, up 6.6% year on year. In the pharmaceuticals segment, strong orders from foreign pharmaceutical companies resulted in revenue of ¥1,375 million, up 3.8% year on year.」

「In the patents segment, orders from patent law firms remained strong, resulting in revenue of ¥497 million, up 2.1% year on year. In the pharmaceuticals segment, the company won projects involving new-drug application materials from domestic and foreign pharmaceutical companies, and orders from CROs also increased, resulting in revenue of ¥727 million, up 13.0% year on year.」

「In the patents segment, strong orders from patent law firms resulted in revenue of ¥1,880 million, up 3.0% year on year. In the pharmaceuticals segment, in addition to stable business with domestic and foreign pharmaceutical companies, expanding orders from CROs and medical-device companies resulted in revenue of ¥2,744 million, up 12.2% year on year.」

「Strong orders from patent law firms resulted in revenue of ¥1,412 million, up 4.8% year on year. In the pharmaceuticals segment, in addition to stable business with foreign pharmaceutical companies, expanding orders from domestic pharmaceutical and medical-device companies resulted in revenue of ¥2,005 million, up 10.9% year on year.」

「In the patents segment, strong orders from patent law firms resulted in revenue of ¥969 million, up 7.3% year on year. In the pharmaceuticals segment, in addition to stable business with foreign pharmaceutical companies, expanding orders from domestic pharmaceutical companies resulted in revenue of ¥1,324 million, up 10.8% year on year.」

「In the patents segment, orders from patent law firms remained strong and orders from corporate intellectual property departments also remained firm, resulting in revenue of ¥487 million, up 11.1% year on year. In the pharmaceuticals segment, in addition to stable business with foreign pharmaceutical companies, expanding orders from domestic pharmaceutical and medical-device companies resulted in revenue of ¥643 million, up 10.4% year on year.」

「In the patent field, although business with patent firms was weak, strong orders from corporate intellectual property departments resulted in revenue growth of 1.3% from the previous fiscal year to ¥1,824 million. In the pharmaceutical field, in addition to stable orders from foreign-affiliated pharmaceutical companies, orders from domestic pharmaceutical companies expanded and the Company won long-term projects from CROs, resulting in revenue growth of 2.8% from the previous fiscal year to ¥2,445 million.」

「In the patent field, orders from corporate intellectual property departments remained strong, but revenue fell 1.1% year on year to ¥1,346 million because business with patent firms was weak. In the pharmaceutical field, in addition to stable orders from foreign-affiliated pharmaceutical companies, orders from domestic pharmaceutical companies expanded and the Company won long-term projects from CROs, resulting in revenue growth of 4.5% year on year to ¥1,807 million.」

「In the patent field, orders from patent firms remained firm, while orders from corporate intellectual property departments remained strong, resulting in revenue growth of 3.1% year on year to ¥903 million. In the pharmaceutical field, in addition to stable orders from foreign-affiliated pharmaceutical companies with which the Company has preferred-vendor agreements, orders from domestic pharmaceutical companies and medical device companies expanded, and the Company also won long-term projects from CROs, resulting in revenue growth of 8.8% year on year to ¥1,193 million.」

「In the patent field, orders from patent firms remained solid, while orders from corporate intellectual property departments also remained strong, resulting in revenue growth of 7.1% year on year to ¥438 million. In the pharmaceutical field, in addition to stable orders from foreign-affiliated pharmaceutical companies with which the Company has preferred-vendor agreements, orders from domestic pharmaceutical companies and medical device companies expanded, and the Company also won long-term projects from CROs, resulting in revenue growth of 10.4% year on year to ¥582 million.」